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Synopsis

25
26

Background: A considerable number of Gram-negative bacteraemias occur outside

27

intensive care units (ICUs). Inadequate antibiotic therapy in ICUs has been associated

28

with adverse outcomes; however, there are no prospective studies in non-ICU patients.

29

Methods: A 6-month (8/1/06-1/31/07), prospective cohort study of non-ICU patients

30

with Gram-negative bacteraemia in a tertiary care hospital was performed. Inadequate

31

empirical antibiotic therapy was defined as no antibiotic or starting a non-susceptible

32

antibiotic within 24 hours after the initial positive blood culture.

33

Results: 250 non-ICU patients had Gram-negative bacteraemia. Mean age=56.4 (±16.1)

34

years. The predominant bacteria in monomicrobial infections were E. coli (24%), K.

35

pneumoniae (18%), and P. aeruginosa (8%). Sixty-one (24%) patients had polymicrobial

36

bacteraemia. Seventy patients (28%) required ICU transfer, and 35 (14%) died.

37

Seventy-nine (31.6%) received inadequate empirical antibiotic therapy. These patients

38

were more likely to have a hospital-acquired infection [Odds ratio (OR)=1.99, 95%

39

confidence interval (CI)=1.11-3.56, p=0.02] and less likely to have E. coli

40

monomicrobial bacteraemia [OR=0.40 (95% CI 0.19-0.86), p=0.02]. There were no

41

differences in occurrence of sepsis [72 (91.1%) patients with inadequate vs. 159 (93.0%)

42

with adequate therapy; p=0.6], ICU transfer [20 (25.3%) vs. 50 (29.2%); p=0.5], post-

43

bacteraemia length of stay (median=6.8 vs. 6.1 days; p=0.09) or death [11 (13.9%) vs. 24

44

(14.0%); p=1.0].

45

Conclusions: Nearly one-third of non-ICU patients with Gram-negative bacteraemia

46

received inadequate empirical antibiotic therapy. There was no difference in adverse

47

outcomes between patients receiving inadequate or adequate therapy in this study.

48

49

Introduction

50
51

Approximately 250,000 episodes of bloodstream infections occur in the United

52

States annually.1 Bloodstream infections have an overall mortality rate of 18%, making

53

them one of the leading causes of death in the U.S.2 Over the last two decades, Gram-

54

negative bacteria have become a less frequent cause of bloodstream infections,3 since the

55

increased use of indwelling vascular devices has resulted in a larger proportion of Gram-

56

positive bacteraemias.1 However, there is evidence that Gram-negative bacteraemias are

57

increasing once again.4 Antibiotic resistance among Gram-negative bacteria is also

58

increasing.5 There has been limited development of new antibiotics with Gram-negative

59

activity,6,7 which has made the treatment of Gram-negative bacteraemia more difficult.

60

Previous studies of bloodstream infections have focused primarily on ICU-

61

acquired infections, because critically ill patients represent a well-defined and highly

62

vulnerable population.8,9 However, bloodstream infections among hospitalized patients

63

outside the ICU account for at least half of all nosocomial bloodstream infections.10

64

These infections in non-ICU patients have rarely been investigated separately.11,12 This is

65

presumably because they were believed to be associated with less morbidity and

66

mortality than in ICU patients, and also because the distribution of non-ICU patients in a

67

hospital requires more workforce to conduct a prospective study. Little data are available

68

on the demographic characteristics of non-ICU patients with Gram-negative bacteraemia,

69

and their clinical outcomes.

70

Several studies have demonstrated that inadequate empirical antibiotic treatment

71

of bacteraemia is associated with poor outcome.13–16 These studies have mainly focused

72

on ICU patients or have been carried out in diverse populations.17 Inadequate empirical

73

treatment was reported in 23-30% of cases in previous studies. However, a 53% rate of

74

inadequate treatment was reported in infections due to antibiotic-resistant organisms.18 If

75

similar rates of inadequate treatment exist in non-ICU patients, empirical antibiotic

76

prescribing practices would need to be re-examined.

77

In this study, we describe the epidemiology of Gram-negative bacteraemia in non-

78

ICU patients at a tertiary-care hospital, investigate the frequency of inadequate antibiotic

79

treatment, elicit predisposing factors for inadequate therapy, and determine its impact on

80

clinical outcomes.

81

82

Patients and Methods

83
84

Setting

85

Barnes-Jewish Hospital (BJH), a 1250-bed teaching hospital, is the largest hospital in

86

Missouri, with a referral base that includes the Saint Louis metropolitan area, eastern

87

Missouri and western Illinois.

88
89

Study design

90

We performed a prospective cohort study of patients with Gram-negative bacteraemia

91

during a 6-month period from August 1st, 2006 until January 31st, 2007. An automated

92

query of all non-ICU patients with a blood culture growing ≥1 species of Gram-negative

93

bacilli was performed using electronic data from a BJC Healthcare clinical data

94

repository and the results were sent daily to one of the investigators (J.M.).

95
96

Inclusion and exclusion criteria

97

All adult patients admitted to non-ICU wards who presented with or developed Gram-

98

negative bacteraemia (≥1 positive blood culture) were included. Polymicrobial infections

99

were also included if at least one Gram-negative organism was present. Subsequent

100

episodes of bacteraemia in study patients were excluded from the analysis. Patients who

101

were bacteraemic as an outpatient (in clinics or in the emergency department) and who

102

were discharged to home before the results of the culture were known were excluded. We

103

also excluded patients who were initially identified as having a Gram-negative

104

bacteraemia, but were determined to have Gram-positive organisms in the final

105

laboratory identification (n=4).

106
107

Data collection

108

Paper and electronic medical records of patients who met inclusion criteria were

109

reviewed for demographics, medical history, home medication, and possible sources of

110

infection. Information on all positive clinical cultures other than blood cultures was also

111

collected to determine any potential focus of infection. Charlson comorbidity19 and

112

McCabe severity of illness20 scores were computed for each patient. Patients’ vital signs,

113

laboratory, pharmacy, and radiological data were continuously reviewed during the

114

admission. Medication information was entered sequentially as start and stop date and

115

time for each antibiotic.

116

Key clinical outcomes measured included the development of hypotension, multiple

117

organ dysfunction syndrome, ARDS, mechanical ventilation, any subsequent transfer to

118

the ICU, length of hospital stay after detection of positive blood cultures, and in-hospital

119

mortality.

120
121

Definitions

122

Adequacy of antibiotic therapy was determined at various time periods: 1) within 24

123

hours of the time the blood culture was drawn, 2) within 24 hours of notification of

124

bacterial growth (which coincided with the notification of Gram stain results), 3) within

125

24 hours of bacterial identification, and 4) within 24, 48, and 72 hours of notification of

126

antibiotic susceptibility results. Inadequacy of antibiotic treatment was defined as no

127

antibiotic or no susceptibility-matching antibiotic administered during each of these time

128

periods in order to reflect the dynamics of inadequate treatment. Various time periods

129

have been examined in the literature, including antibiotic treatment during a period of 24

130

hours from time of blood culture sampling,18,21,14,13,22 at the time when antibiotic

131

susceptibility results are available,23,15 or during 48 hours from the time of notification of

132

susceptibilities.17 We analyzed inadequate treatment within 24 hours of blood culture

133

sampling, since this definition has been used in the largest number of studies. If antibiotic

134

susceptibility testing was not performed, we decided on a case-by-case basis whether

135

treatment could be considered adequate, based on the antibiogram for that particular

136

organism at Barnes-Jewish Hospital. Multi-drug resistance was defined using previously

137

published criteria.24

138

Sepsis, sepsis-induced hypotension, and multiple organ dysfunction syndrome were

139

defined using established criteria.25 A bacteraemia was classified as community-acquired

140

if the first positive blood culture occurred ≤48 hours after hospital admission.26

141

Neutropenia was defined as white blood cell count <1.0 G/L. Medical

142

immunosuppression was defined as receipt of prednisone equivalent of ≥10mg daily or

143

any other immunosuppressant (e.g., cyclosporine, methotrexate, etc.) during the 30 days

144

prior to admission.

145
146

Microbiological methods

147

Work-up of all blood cultures was performed by the BJH Clinical Microbiology

148

Laboratory. Blood cultures were incubated in the Bactec 9240 system (Becton-Dickinson

149

Diagnostic Systems, Sparks, MD). Standard microbiological methods for identification

150

and antibiotic susceptibility testing were employed.27

151

In our institution, the microbiology laboratory notifies the clinician when a blood culture

152

becomes positive. Following notification, the clinician is responsible for reviewing

153

subsequent bacterial identification and antimicrobial susceptibility results in the hospital

154

computer system.

155
156

Data analysis and statistical methods

157

Data entry was performed using Microsoft Access and Excel (Microsoft Corp., Redmond,

158

WA), and data analysis was performed using SPSS 14 (SPSS Inc., Chicago, IL).
2

159

Univariate comparisons among categorical variables were performed using the

160

test or Fisher’s exact test as appropriate. Comparisons among continuous independent

161

variables were performed using Student’s t test or Mann Whitney U test as appropriate. A

162

two-sided p value of <0.05 was considered significant. Variables found to have a p<0.1

163

on univariate testing were considered for entry into a forward stepwise multivariate

164

logistic regression model. The study was approved by the Washington University Human

165

Research Protection Office (No. 06-0638). Due to the observational design of the study

166

informed consent was not required.

167

168

Results

169
170

The epidemiology of Gram-negative bacteraemia outside the ICU

171

Two hundred and ninety-four patients had a Gram-negative bacteraemia during the study

172

period. Of these, 44 (15.0%) patients were ICU patients, leaving 250 patients for analysis

173

(Table 1).

174

There were 160 (64.0%) community-acquired and 90 (36.0%) hospital-acquired

175

infections. The predominant organisms in monomicrobial bacteraemias were E. coli

176

(n=59; 24%), K. pneumoniae (45; 18%), and P. aeruginosa (19; 8%). Sixty-one

177

bacteraemias were polymicrobial (24.4%) (Table 2). There were 12 (4.8%) multi-drug

178

resistant organisms among the isolates.

179

Two hundred and thirty-one (92.4%) patients were septic at the time of blood culture, 105

180

(42.0%) developed hypotension, and 11 (4.4%) multiple organ dysfunction syndrome.

181

Transfer to ICU was necessary in 70 (28.0%) patients. In-hospital mortality was 14.0%

182

(n=35).

183
184

The frequency of inadequate antibiotic treatment of Gram-negative bacteraemia

185

The antibiotics with Gram-negative activity that were most frequently prescribed during

186

the 24-hour period after the initial positive blood culture was drawn were cefepime (109;

187

in 43.6% of episodes), ciprofloxacin (57; 22.8%), piperacillin/tazobactam (39; 15.6%),

188

gentamicin (28; 11.2%), ceftriaxone (22; 8.8%), meropenem (9; 3.6%), and

189

ampicillin/sulbactam (5; 2.0%). In 57 cases (22.8%) more than one antibiotic was given

190

in this time period.

191

Seventy-nine (31.6%) patients received inadequate empirical antibiotic treatment. In 38

192

(48.1%) of cases inadequate treatment was due to failure to administer antibiotics with

193

Gram-negative coverage within 24 hours of the initial positive blood culture, and in 41

194

(51.9%) cases was due to a Gram-negative bacillus that was resistant to the prescribed

195

antibiotic. Within 24 hours after notification of antibiotic susceptibilities, 28 of 197

196

patients (14.2%) were still receiving inadequate antibiotic treatment (Figure 1).

197
198

Factors associated with inadequate empirical antibiotic treatment of Gram-negative

199

bacteraemia

200

Among patients receiving inadequate versus adequate empirical treatment within the first

201

24 hours after the initial blood culture was drawn, there were no significant differences in

202

mean age [55.3 years (±17.0) vs. 56.9 years (±15.8), p=0.5], male gender [43 (54.4%) vs.

203

83 (48.5%), p=0.4], body mass index (median 25.3 vs. 27.3, p=0.12), Charlson score

204

(median 3 vs. 4, p=0.4), McCabe score (median 1 vs. 1, p=0.2) (Table 1), or in type of

205

service admitting the patient (data not shown). Patients with hospital-acquired

206

bacteraemia were more often inadequately treated than those with community-acquired

207

bacteraemia [37 (46.8%) vs. 53 (31.0%) patients, p=0.02].

208

E. coli was less likely to be the cause of inadequately treated bacteraemia [10

209

(12.7%) vs. 49 (28.7%), p=0.006]. Apart from resistance to ampicillin (58% of

210

monomicrobial E. coli bacteraemias), E. coli were most often resistant to

211

trimethoprim/sulfamethoxazole (21; 35.6%), ciprofloxacin (18; 30.5%), gentamicin (7;

212

11.9%), and piperacillin/tazobactam (2; 3.4%). Treatment was less often inadequate if the

213

bloodstream infection had a urinary tract source, [14 (20.9%) urinary vs. 65 (35.5%) non-

214

urinary source, p=0.03].

215

In multivariate analysis, hospital-acquired bacteraemia [OR 1.99 (95% CI 1.11-

216

3.56), p=0.02] was associated with receiving inadequate empirical antibiotic treatment.

217

Mucositis at time of blood culture [OR 0.23 (95% CI 0.06-0.84), p=0.03], and presence

218

of E. coli monomicrobial bacteraemia [OR 0.40 (95% CI 0.19-0.86), p=0.02] were more

219

commonly associated with adequate antibiotic use (Table 1).

220
221

The outcome of inadequately empirically treated Gram-negative bacteraemia

222

Comparing the outcomes of inadequately versus adequately treated infections, there were

223

no differences in transfer to the ICU [20 (25.3%) vs. 50 (29.2%), p=0.5], length of

224

hospital stay after positive blood culture [median 6.8 days (range 1-89) vs. 6.1 days (1-

225

106), p=0.09], or in-hospital mortality [11 (13.9%) vs. 24 (14.0%), p=1.0]. When

226

adjusting the effect of inadequate treatment for the Charlson comorbidity score, previous

227

exposure to steroids, and neutropenia (all of which had been found to be associated with

228

mortality in univariate analysis), inadequate treatment did not remain in the final model

229

(data not shown). There was no difference in mortality whether cefepime had been used

230

for empirical treatment or not [17 (15.6%) patients exposed to cefepime vs. 18 (12.8%)

231

not exposed; p=0.5].

232

Definitive treatment (defined as administration of an antibiotic that matched the

233

bacteria’s susceptibility pattern within 24 hours of notification of susceptibilities) was

234

more often inadequate if empirical antibiotic treatment had been inadequate compared to

235

if it had been adequate [20 (30.8%) with inadequate empirical therapy vs. 8 (6.1%) with

236

adequate empirical therapy, p<0.001].

237

238

Discussion

239
240

Non-ICU patients account for approximately half of the bloodstream infections in the

241

hospital.2,10 An even larger proportion of Gram-negative bacteraemias (62-95%) occurs

242

in non-ICU patients.28–30 Nevertheless, bacteraemias have rarely been investigated

243

outside the intensive care unit,11,12,31 which may be due to the heterogeneity of non-ICU

244

patients. To our knowledge, this is the first prospective study of Gram-negative

245

bacteraemia in the non-ICU hospitalized population. During the study period, non-ICU

246

patients accounted for 85% (250 of 294) of all Gram-negative bacteraemias in this

247

hospital. The demographics, comorbidities, and microbiology of infections in this study

248

are similar to retrospective studies of Gram-negative bacteraemias in hospitalized

249

patients.28,29,32,33 Urinary tract infections were the predominant source of bacteraemia and

250

E. coli was the most frequently detected organism. This is in contrast to Gram-negative

251

bacteraemias in ICU patients, which frequently originate from the respiratory34 or

252

gastrointestinal tract35 and are more often caused by P. aeruginosa.31

253

Twenty-eight percent of patients were transferred to the ICU after the bacteraemia

254

had occurred. The in-hospital mortality was substantial (14%), but less than the 24%

255

mortality rate in a Danish population-based study,28 or in studies of ICU patients with

256

Gram-negative bacteraemia (49-60%).34,35 This is likely due to differences in population

257

characteristics including different levels of severity of underlying illnesses, but might

258

also point to differences in the management of sepsis rather than antibiotic treatment.

259

260

One of the major modifiable factors influencing the outcome of bacteraemia is the

261

adequacy of antibiotic treatment.36 This was demonstrated in studies including ICU

262

patients.13-17,23 However, no study has examined the effect of adequate antibiotic

263

treatment on outcomes in non-ICU patients only. We demonstrated rates of inadequate

264

empirical treatment during the first 24 hours after the blood culture (31.6%) similar to the

265

30% - 37% reported from other prospective studies.15,17 In approximately half of the

266

cases, inadequate treatment was due to failure to administer an antibiotic with Gram-

267

negative activity.

268

Hospital-acquired bacteraemia was a risk factor for receiving inadequate

269

empirical antibiotic treatment in our cohort. This has been noted previously,22,21,13-15 and

270

suggests that physicians are often unaware of the different microbiological patterns in the

271

hospital versus the community. Increasing antibiotic resistance and lack of prescriber

272

knowledge regarding appropriate antibiotics for likely in-hospital pathogens may lead to

273

the institution of inadequate empirical antibiotic treatment. Decision support tools, based

274

on local bacterial antimicrobial resistance patterns in association with clinical information

275

and inclusion of Gram stain results, may improve the choice of empirical therapy.37,38

276

Several other risk factors for inadequate treatment have been found, e.g. previous

277

antibiotic treatment,14,13 hospital admission in the 90 days prior to the current

278

admission,21 polymicrobial infections,14 and Pseudomonas infections,22 which we did not

279

find. Conversely, E. coli infection was associated with less risk of inadequate treatment,

280

which has been reported before by others.22,13 E. coli is the most frequent cause of Gram-

281

negative bacteraemia and is not as prone to multi-drug resistance as other Gram-negative

282

bacteria,33 which may explain why it is generally better covered by empirical

283

antimicrobials. The finding that mucositis was protective against inadequate treatment

284

might be related to mucositis being more often present in a subset of oncology patients,

285

and a tendency to start broad-spectrum antibiotics with Gram-negative activity earlier in

286

this population.

287
288

In our cohort of patients, inadequate empirical treatment was not associated with

289

deterioration of status (transfer to ICU, length of hospital stay, or increased in-hospital

290

mortality). This is in contrast to many studies, in which inadequate treatment was

291

associated with adverse outcomes.13-17,23 However, a few studies that included mixed ICU

292

and non-ICU patient populations have not found this association.22,21 One possible

293

explanation for our finding is that non-ICU patients in general have a lower severity of

294

illness compared to ICU patients and therefore, the role of the adequate antibiotic

295

treatment may be less crucial.36 A study underlining this assumption showed that

296

inadequate treatment was more frequently administered in less severely ill patients, with

297

no discernable impact on outcomes.22 Interventions focused on optimizing treatment for

298

non-ICU patients would likely have the greatest benefit in e.g., neutropenic patients,

299

transplant patients, and patients at risk for Pseudomonas bacteraemia.

300
301

In addition, we did not find that the use of cefepime for empirical treatment was
associated with increased all-cause mortality as a recent meta-analysis has reported.39

302
303

There are some limitations to our study. First, this is a single, tertiary care hospital

304

and may reflect process issues unique to this facility. In our hospital the clinician is only

305

directly notified by the microbiology laboratory when a blood culture turns positive, but

306

needs to look up subsequent bacterial identification and antimicrobial susceptibility

307

results in the hospital computer system. This may cause delays in starting adequate

308

antibiotic treatment. We also only collected crude mortality, not attributable mortality.

309

The sample size is large for a single-center prospective study but may still be small to

310

detect a difference in outcomes, like Fraser and colleagues reported from a mixed ICU

311

and non-ICU population.40

312

One of the strengths of this prospective study is the detailed sequential analysis of

313

the adequacy of antibiotic treatment at different time points. Previous studies of the

314

adequacy of treatment have analyzed one specific time frame and not taken into account

315

the dynamic that is inherent in the processing of blood cultures and the notification of

316

results to the treating physician. We also evaluated empirical and definitive therapy

317

separately, and controlled for baseline severity of illness.41 At our institution, antibiotic

318

treatment is initiated by clinicians from various specialties and levels of professional

319

experience and is therefore diverse, which adds to the generalizability of our findings.

320
321

Our study is the first to prospectively describe the epidemiology of Gram-

322

negative bacteraemias in non-ICU patients. The frequency of inadequate empirical

323

antibiotic treatment is similar to data from ICUs. The administration of inadequate

324

treatment did not confer worse patient outcomes. Therefore, while adequate antibiotic

325

therapy is an important factor, our findings suggest that there are other factors that may

326

be more important in determining the prognosis in the non-ICU population.

327
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Table 1. Comparison of 250 non-ICU patients receiving inadequate versus adequate empirical antibiotic treatment for Gram-

468

negative bacteraemia
Total

Univariate analysis

Multivariate
analysis

n (%)

Inadequate treatment

Adequate treatment

p value

Odds Ratio (95%

(n=79)

(n=171)

56.4 (±16.1)

55.3 years (±17.0)

56.9 years (±15.8)

0.5

-

126 (50.4%)

43 (54.4%)

83 (48.5%)

0.4

-

153 (61.2%)
94 (37.6%)
3 (1.2%)
33 (13.2%)
146 (58.4%)
26.4 (13.3-70.4)
4 (0-16)

12 (15.2%)
46 (58.2%)
25.3 (17.0-70.4)
3 (0-16)

21 (12.3%)
100 (58.5%)
27.3 (13.3-66.4)
4 (0-15)

0.5
1.0
0.12
0.4

-

1 (1-3)

1 (1-3)

1 (1-3)

0.2

-

30 (12.0%)
44 (17.6%)
112 (44.8%)
27 (10.8%)

6 (7.6%)
15 (19.0%)
31 (39.2%)
5 (6.3%)

24 (14.0%)
29 (17.0%)
81 (47.4%)
22 (12.9%)

0.15
0.7
0.2
0.12

-

(n=250)

Age, mean ( standard deviation),
years
Male gender
Race
- White
- African-American
- Other
LTCF resident
Admitted within 3 months
BMI (median, range), kg/m2
Charlson comorbidity score (median,
range)
McCabe severity of illness score
(median, range)
Congestive heart failure
Chronic pulmonary disease
Malignancy
- Leukaemia

CI)

25

- Metastatic solid tumor
- Neutropenia
- Chemotherapy ≤30 days prior to
admission
Received steroids ≤30 days prior to
admission
Other immunosuppressive therapy
History of solid organ transplant
Bone marrow transplant (this
admission)
Diabetes mellitus
Hyperglycemia (>200 mg/dL)
Renal insufficiency (Cr >1.5 mg/dL)
Cerebrovascular disease
Hemiplegia
Liver disease
Mucositis at time of blood culture
Source of bloodstream infection
- Urinary tract
- Intravascular catheter
- GI tract
- Respiratory tract
- Other source
- No source identified
Hospital-acquired bacteraemia
E. coli, monomicrobial infection
K. pneumoniae, monomicrobial
infection

34 (13.6%)
36 (14.4%)
31 (12.4%)

10 (12.7%)
8 (10.1%)

24 (14.0%)
28 (16.4%)

0.8
0.2

-

87 (34.8%)
41 (16.4%)
68 (27.2%)
28 (11.2%)
15 (6.0%)
26 (10.4%)
21 (8.4%)

22 (27.8%)
8 (10.1%)
25 (31.6%)
7 (8.9%)
8 (10.1%)
12 (15.2%)
3 (3.8%)

65 (38.0%)
33 (19.3%)
43 (25.1%)
21 (12.3%)
7 (4.1%)
14 (8.2%)
18 (10.5%)

0.12
0.07
0.3
0.4
0.06
0.09
0.08

0.23 (0.06-0.84)

67 (26.8%)
40 (16.0%)
41 (16.4%)
9 (3.6%)
28 (11.2%)
65 (26.0%)
90 (36%)
59 (23.6%)
45 (18.0%)

14 (17.7%)
18 (22.8%)

53 (31.0%)
22 (12.9%)

0.03
0.047

-

37 (46.8%)
10 (12.7%)
11 (13.9%)

53 (31.0%)
49 (28.7%)
34 (19.9%)

0.02
0.006
0.3

1.99 (1.11-3.56)
0.40 (0.19-0.86)
-

35 (14.0%)
30 (12.0%)
10 (4.0%)
10 (4.0%)

26

P. aeruginosa, monomicrobial
infection
Polymicrobial infection
Sepsis
Sepsis-induced hypotension
Outcomes
- Multiple organ dysfunction
syndrome
- Transfer to intensive care unit (ICU)
- Mechanical ventilation after
bacteraemia
- ARDS
- In-hospital mortality

19 (7.6%)

7 (8.9%)

12 (7.0%)

0.6

-

61 (24.4%)
231 (92.4%)
105 (42.0%)

24 (30.4%)
72 (91.1%)
32 (40.5%)

37 (21.6%)
159 (93.0%)
73 (42.7%)

0.14
0.6
0.7

-

20 (25.3%)

50 (29.2%)

0.5

-

11 (13.9%)

24 (14.0%)

1.0

-

11 (4.4%)
70 (28.0%)
29 (11.6%)
6 (2.4%)
35 (14.0%)

469
470

NOTE. LTCF = Long-term care facility. BMI = Body mass index. GI tract = Gastrointestinal tract. ARDS = Acute respiratory distress

471

syndrome. Variables considered for entry in a forward stepwise multivariate logistic regression model included Hospital-acquired

472

infection; Source, urinary tract; Source, intravascular catheter; Hemiplegia; E. coli, monomicrobial infection; Hyperglycemia;

473

Mucositis; Liver disease. The -2 log likelihood value for the final model was 293.796, and the Hosmer-Lemeshow goodness-of-fit chi

474

square test was 0.861 (p=0.835).

475

27

476

Table 2. Bacterial isolates in 250 non-ICU patients with Gram-negative bacteraemia
Microorganism
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Enterobacter cloacae
Proteus mirabilis
Acinetobacter baumannii
Klebsiella oxytoca
Stenotrophomonas maltophilia
Other Gram-negative microorganisms

n (%)
n=274
77 (28%)
67 (24%)
30 (11%)
15 (5%)
13 (5%)
13 (5%)
8 (3%)
6 (2%)
45 (16%)

477
478

NOTE. Sixty-one (24.4%) of 250 Gram-negative bacteraemia episodes were polymicrobial infections. The most frequent among the

479

45 other Gram-negative organisms were Enterobacter aerogenes (4), Achromobacter spp. (3), Acinetobacter spp. (3), Citrobacter

480

freundii (3), Citrobacter koseri (3), Providencia spp. (3), Pseudomonas spp. (3), and Salmonella spp. (3).
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481

Figure 1. Inadequate antibiotic treatment among non-ICU patients with Gram-negative bacteraemia

482
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483

NOTE. Denominator changes due to patient discharge or death.
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